Emmanuelle Josselin
Marseille, 13009, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
CRL2FEM1B uses heme to recruit BACH1 for degradation and regulate ferroptosis in lung cancer.
Journal: Molecular cell
Published: May 08, 2025
ETx-22, a Novel Nectin-4-Directed Antibody-Drug Conjugate, Demonstrates Safety and Potent Antitumor Activity in Low-Nectin-4-Expressing Tumors.
Journal: Cancer research communications
Published: March 22, 2024
mTert induction in p21-positive cells counteracts capillary rarefaction and pulmonary emphysema.
Journal: EMBO reports
Published: October 06, 2023
INA03: A Potent Transferrin-Competitive Antibody-Drug Conjugate against CD71 for Safer Acute Leukemia Treatment.
Journal: Molecular cancer therapeutics
Published: August 22, 2023
Targeting CISH enhances natural cytotoxicity receptor signaling and reduces NK cell exhaustion to improve solid tumor immunity.
Journal: Journal for immunotherapy of cancer
Published: April 06, 2022
BMI1 nuclear location is critical for RAD51-dependent response to replication stress and drives chemoresistance in breast cancer stem cells.
Journal: Cell death & disease
Published: September 01, 2021
Modeling Heterogeneity of Triple-Negative Breast Cancer Uncovers a Novel Combinatorial Treatment Overcoming Primary Drug Resistance.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: August 10, 2020
Correction to A Novel Covalent mTOR Inhibitor, DHM25, Shows in Vivo Antitumor Activity against Triple-Negative Breast Cancer Cells.
Journal: Journal of medicinal chemistry
Published: October 12, 2019
Vitamin D Controls Tumor Growth and CD8+ T Cell Infiltration in Breast Cancer.
Journal: Frontiers in immunology
Published: March 15, 2019
A Bispecific Antibody-Based Approach for Targeting Mesothelin in Triple Negative Breast Cancer.
Journal: Frontiers in immunology
Published: December 13, 2018
A genome-wide RNAi screen reveals essential therapeutic targets of breast cancer stem cells.
Journal: EMBO molecular medicine
Published: October 13, 2018
The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/β-Catenin Signaling.
The SCRIB Paralog LANO/LRRC1 Regulates Breast Cancer Stem Cell Fate through WNT/β-Catenin Signaling.
Journal: Stem cell reports
Published: December 14, 2017
Last Updated: 09/26/2026